Semaglutide Tablet shortage
To Be Discontinued 3 presentations · 1 manufacturers · first FDA posting 2026-06-04 · last update 2026-06-04
Manufacturers: Novo Nordisk, Inc.
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Rybelsus, Tablet, 3 mg (NDC 0169-4303-30) | Novo Nordisk, Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets. | Posted 06/04/2026 Updated 06/04/2026 Discontinued 06/04/2026 |
| Rybelsus, Tablet, 7 mg (NDC 0169-4307-30) | Novo Nordisk, Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets. | Posted 06/04/2026 Updated 06/04/2026 Discontinued 06/04/2026 |
| Rybelsus, Tablet, 14 mg (NDC 0169-4314-30) | Novo Nordisk, Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets. | Posted 06/04/2026 Updated 06/04/2026 Discontinued 06/04/2026 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)